- Report
- November 2023
- 30 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Report
- November 2023
- 630 Pages
Global
From €9159EUR$9,500USD£7,833GBP
- Report
- January 2024
- 215 Pages
Global
From €7665EUR$7,950USD£6,555GBP
- Report
- December 2022
- 153 Pages
Global
From €5062EUR$5,250USD£4,329GBP
- Report
- May 2022
- 510 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- May 2020
- 482 Pages
Global
From €9159EUR$9,500USD£7,833GBP
- Report
- July 2019
Global
From €964EUR$1,000USD£825GBP
- Report
- January 2024
- 146 Pages
Japan
From €3615EUR$3,750USD£3,092GBP
- Report
- November 2020
- 49 Pages
Global
€1271EUR$1,318USD£1,087GBP
- Drug Pipelines
- September 2019
- 57 Pages
Global
€9641EUR$10,000USD£8,245GBP
- Report
- April 2021
- 191 Pages
Global
€21210EUR$22,000USD£18,140GBP
- Report
- July 2018
- 199 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- April 2019
- 93 Pages
Global
From €3133EUR$3,250USD£2,680GBP
Imfinzi (durvalumab) is a monoclonal antibody drug used to treat certain types of non-small cell lung cancer (NSCLC). It is used in combination with other drugs to treat patients with locally advanced or metastatic NSCLC who have not received prior treatment. Imfinzi works by blocking the action of a protein called PD-L1, which helps cancer cells to evade the body's immune system. Imfinzi is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and is currently being studied in clinical trials for other types of cancer.
The Imfinzi market is highly competitive, with several major pharmaceutical companies developing and marketing drugs for the treatment of NSCLC. These include AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, and Roche. Other companies, such as AbbVie, Amgen, and Novartis, are also developing drugs for the treatment of NSCLC. Show Less Read more
